Inventage Lab

Inventage Lab FCF/Net Income

The Free Cash Flow to Net Income Ratio of Inventage Lab (389470.KQ) as of Nov 3, 2026 is 325.98 %. In the previous year, Free Cash Flow to Net Income Ratio was 105.81 % — a change of 208.07% (higher).

FCF/Net Income

325.98 %

YoY

208.07%

Last updated:

Free Cash Flow to Net Income Ratio of Inventage Lab is 2025 325.98 % . Free Cash Flow to Net Income Ratio of Inventage Lab was 2024 105.81 % . It decreases by 208.07% higher compared to the previous year.

The Inventage Lab FCF/Net Income history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Net Income
Date
FCF/Net Income
Jan 1, 2019
43.58 KRW
Jan 1, 2020
43.69 KRW
Jan 1, 2021
118.75 KRW
Jan 1, 2022
67.66 KRW
Jan 1, 2023
69.84 KRW
Jan 1, 2024
105.81 KRW
Jan 1, 2025
325.98 KRW
The Inventage Lab FCF/Net Income history
YEARFCF/Net IncomeYoY
325.98 %+208.07%
105.81 %+51.51%
69.84 %+3.22%
67.66 %-43.02%
118.75 %+171.83%
43.69 %+0.24%
43.58 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Inventage Lab Stock analysis

What does Inventage Lab do? Inventage Lab, Inc. generates revenue through the research, manufacture, and sale of human medicines targeting male pattern baldness, dementia, and prostate cancer, as well as veterinary medicines including combination drugs and chemical castration agents. The company leverages its proprietary platforms for long-acting injections and genetic material drug delivery to develop and scale production of these products. Its human medicine segment focuses on therapeutic areas with significant market demand, while veterinary medicines serve agricultural and companion animal markets. The firm's business model centers on proprietary technology platforms applied to both human and veterinary pharmaceutical development. These platforms enable the company to create and mass-produce innovative drug delivery systems, which are critical for the efficacy of their medicine portfolios. Revenue streams are derived from direct sales of these medicines to healthcare providers and veterinary institutions within their target markets. Inventage Lab, Inc. operates with a dual focus on human and veterinary pharmaceuticals, utilizing its specialized platforms to address unmet medical needs in both sectors. The company's product range includes treatments for specific conditions like male pattern baldness and prostate cancer, alongside veterinary applications such as chemical castration agents, which are sold to relevant industry stakeholders in their respective markets. Inventage Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Inventage Lab stock

Free Cash Flow to Net Income Ratio of Inventage Lab is 325.98 % in 2025.

Free Cash Flow to Net Income Ratio of Inventage Lab changed from 105.81 % to 325.98 %, representing a 208.07% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Net Income Ratio Inventage Lab since 2006 – with annual values, charts, and detailed analysis.

The FCF/Net Income ratio measures cash flow quality. Ratios consistently above 100% suggest high-quality earnings with strong cash backing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Net Income Ratio's Inventage Lab with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow to Net Income Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow to Net Income Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Inventage Lab

All Key Metrics — Inventage Lab